keyword
MENU ▼
Read by QxMD icon Read
search

Virus C and liver transplantation

keyword
https://www.readbyqxmd.com/read/28804572/bacterial-infections-post-living-donor-liver-transplantation-in-egyptian-hepatitis-c-virus-cirrhotic-patients-a-single-center-study
#1
Mohamed F Montasser, Nadia A Abdelkader, Sara M Abdelhakam, Hany Dabbous, Iman F Montasser, Yasmine M Massoud, Waleed Abdelmoaty, Shereen A Saleh, Mohamed Bahaa, Hany Said, Mahmoud El-Meteini
AIM: To determine risk factors, causative organisms and antimicrobial resistance of bacterial infections following living-donor liver transplantation (LDLT) in cirrhotic patients. METHODS: This prospective study included 45 patients with hepatitis C virus-related end-stage liver disease who underwent LDLT at Ain Shams Center for Organ Transplant, Cairo, Egypt from January 2014 to November 2015. Patients were followed-up for the first 3 mo after LDLT for detection of bacterial infections...
July 18, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28804513/noncirrhotic-hepatocellular-carcinoma-etiology-and-occult-hepatitis-b-virus-infection-in-a-hepatitis-b-virus-endemic-area
#2
Chang Woo Shim, Joong-Won Park, So Hee Kim, Jin Sook Kim, Bo Hyun Kim, Sung Hoon Kim, Eun Kyung Hong
BACKGROUND: Although hepatocellular carcinoma (HCC) usually develops in cirrhotic livers, a minority of cases occur in noncirrhotic livers (NCLs). We investigated etiology, clinicopathological features, and occult hepatitis B virus (HBV) infection (OBI) in patients with NCL HCC in an HBV-endemic area. METHODS: A total of 710 patients who underwent resection or transplantation for HCC at the National Cancer Center (NCC), Korea, were enrolled. HCC and fibrosis stage were diagnosed pathologically...
July 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28800720/jc-virus-related-progressive-multifocal-leukoencephalopathy-after-living-donor-liver-transplant-a-rare-case
#3
Archana Rastogi, Natasha Gulati, Chhagan Bihari, Ashok Chaudhary, Kalpana Bansal, Shridhar Sasturkar, Shalini Thapar, Viniyendra Pamecha
Progressive multifocal leukoencephalopathy caused by polyoma JC virus is a rare and severe demyelinating disease of the central nervous system. It occurs in immunocompromised patients and is scarcely reported in liver transplant recipients. Brain biopsy demonstrating demyelination with presence of foamy macrophages, relative preservation of axons, astrogliosis, and typical polyomavirus inclusions in the enlarged oligodendroglial nuclei is essential for diagnosis. Here, we report a case of JC virus-associated progressive multifocal leukoencephalopathy in a living-donor liver transplant recipient who was transplanted for hepatitis C virus-related decompensated cirrhosis...
August 12, 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/28798283/healthcare-costs-for-chronic-hepatitis-c-in-south-korea-from-2009-to-2013-an-analysis-of-the-national-health-insurance-claims-data
#4
Moran Ki, Hwa Young Choi, Kyung-Ah Kim, Eun Sun Jang, Sook-Hyang Jeong
Background/Aims: The introduction of direct-acting antivirals (DAA) in 2013 revolutionized hepatitis C virus (HCV) treatment, offering a cure rate >90%. However, this therapy is expensive, and estimations of the number of chronic HCV-infected (CHC) patients and their treatment costs pre-2013 are therefore essential for creating policies and expanding drug access. Herein, we aimed to investigate the number of HCV-related liver disease patients, their healthcare utilization, their annual direct medical costs, and the interferon-based antiviral treatment rates and costs from 2009 to 2013 in South Korea...
August 14, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28795982/treatment-of-patients-with-hepatitis-c-virus-infection-genotype-4-with-ledipasvir-sofosbuvir-in-the-liver-transplant-setting
#5
Faisal Abaalkhail, Hussein Elsiesy, Hany Elbeshbeshy, Mohamed Shawkat, Sarra Yousif, Waheed Ullah, Saleh Alabbad, Ahmed Al-Jedai, Aziza Ajlan, Dieter Broering, Sammy Saab, Mohammed Al Sebayel, Waleed Al-Hamoudi
BACKGROUND: Hepatitis C virus infection is a major cause of liver cirrhosis and hepatocellular carcinoma and the leading indication for liver transplantation. In the Middle East, genotype 4 HCV infection is the most common genotype. However, limited data exists on the treatment of genotype-4 in the liver transplant setting. We evaluated the safety and efficacy of ledipasvir-sofosbuvir (LDV/SOF) in treating HCV genotype-4 infected patients with cirrhosis or postliver transplantation. METHODS: This prospective, single-arm, observational study includes cohort of patients with cirrhosis before liver transplantation (Cohort A) and a cohort of postliver transplantation patients (Cohort B)...
August 9, 2017: Transplantation
https://www.readbyqxmd.com/read/28790832/combination-of-sofosbuvir-and-daclatasvir-in-the-treatment-of-genotype-3-chronic-hepatitis-c-virus-infection-in-patients-on-maintenance-hemodialysis
#6
Jan Sperl, Sona Frankova, Miluse Kreidlova, Dusan Merta, Monika Tothova, Julius Spicak
Chronic hepatitis C virus infection (HCV) has a negative impact on the long-term survival of recipients of kidney transplants. HCV should be treated in hemodialyzed patients before their enlistment for kidney transplantation in order to avoid the reactivation of virus after transplantation. Direct-acting antivirals represent the current standard of care in hemodialyzed patients with HCV genotypes 1 and 4; in patients with genotypes 2 or 3, the optimal regimen is yet to be established. Sofosbuvir (SOF) and daclatasvir (DCV) represent an antiviral pangenotypic regimen with favorable pharmacokinetics in hemodialyzed patients...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28780074/intra-hepatic-depletion-of-mucosal-associated-invariant-t-cells-in-hepatitis-c-virus-induced-liver-inflammation
#7
Fabian J Bolte, Ashley C O'Keefe, Lauren M Webb, Elisavet Serti, Elenita Rivera, T Jake Liang, Marc Ghany, Barbara Rehermann
BACKGROUND & AIMS: Chronic hepatitis affects phenotypes of innate and adaptive immune cells. Mucosal associated invariant T (MAIT) cells are enriched in the liver as compared to the blood, respond to intra-hepatic cytokines, and (via the semi-invariant T-cell receptor) to bacteria translocated from the gut. Little is known about the role of MAIT cells in livers of patients with chronic hepatitis C virus (HCV) infection and their fate after antiviral therapy. METHODS: We collected blood samples from 42 patients with chronic HCV infection who achieved a sustained virologic response after 12 weeks of treatment with sofosbuvir and velpatasvir...
August 2, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28774261/modelling-the-burden-of-hepatitis-c-infection-among-people-who-inject-drugs-in-norway-1973-2030
#8
Hinta Meijerink, Richard A White, Astrid Løvlie, Birgitte Freiesleben de Blasio, Olav Dalgard, Ellen J Amundsen, Espen Melum, Hilde Kløvstad
BACKGROUND: Lack of Hepatitis C virus (HCV) incidence data in (Norwegian) high-risk groups impedes the ability to make informed decisions on prevention measures. Thus we rely on modelling to estimate the incidence and burden of HCV infections. METHODS: We constructed a compartmental model for HCV infections in Norway among active and former people who inject drugs (PWIDs). We based yearly transition rates on literature. The model was fitted to absolute numbers of hepatitis C associated cirrhosis, hepatocellular carcinoma (HCC) and death from national data sources (2000-2013)...
August 3, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28762681/-novel-antiviral-agents-for-the-treatment-of-hcv-among-renal-transplant-recipients
#9
REVIEW
Fabrizio Fabrizi, Francesca M Donato, Piergiorgio Messa
The frequency of hepatitis C virus infection remains high in renal transplant recipients and plays a detrimental role on survival in this population. According to the latest evidence, the adjusted relative risk of mortality and graft loss for anti-HCV seropositive versus anti-HCV negative renal transplant recipients was 1.85 with a 95% confidence interval (CI) of 1.49 ; 2.31 (P < 0.0001) and 1.76 (95% CI, 1.46 ; 2.11) (P < 0.0001), respectively. Interferon-based regimens have been recommended for the treatment of hepatitis C after renal transplantation only in selected circumstances because of an increased risk of acute rejection due to the immuno-stimulatory properties of interferon...
August 1, 2017: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/28756716/impact-of-hepatitis-c-virus-infection-on-health-related-quality-of-life-before-and-after-liver-transplantation-a-multidisciplinary-point-of-view
#10
Lucia Golfieri, Stefano Gitto, Maria Cristina Morelli, Antonio Daniele Pinna, Silvana Grandi, Pietro Andreone
Hepatitis C negatively changes patient quality of life even in the absence of advanced liver disease. The specific patterns of quality of life of hepatitis C positive patients waiting for transplant or after surgery are not widely studied. Areas covered: A significant percentage of infected patients show cognitive impairment, fatigue, and/or a 'brain fog', that cannot be explained by the liver disease. Depression can be diagnosed in one third of hepatitis C positive patients. Conflicting data are available regarding the possible role of Model for End-Stage Liver Disease score as predictor of impaired quality of life...
August 2017: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/28752925/management-of-portal-hypertension-before-and-after-liver-transplantation
#11
L W Unger, G Berlakovich, M Trauner, T Reiberger
Orthotopic liver transplantation (OLT) represents a curative treatment option for end-stage liver disease (ESLD). While epidemiology of ESLD has recently changed due the rising prevalence of non-alcoholic fatty liver disease (NAFLD) and decreased burden of hepatitis C virus (HCV) infections due to highly-effective antiviral regimens, the management of portal hypertension (PHT) remains a clinical challenge in the pre- and post-OLT setting. The measurement of hepatic venous pressure gradient (HVPG) represents the most reliable, but invasive tool for assessment of the severity of PHT...
July 28, 2017: Liver Transplantation
https://www.readbyqxmd.com/read/28750044/hcv-replication-in-gastrointestinal-mucosa-potential-extra-hepatic-viral-reservoir-and-possible-role-in-hcv-infection-recurrence-after-liver-transplantation
#12
Giovanna Russelli, Paola Pizzillo, Gioacchin Iannolo, Floriana Barbera, Fabio Tuzzolino, Rosa Liotta, Mario Traina, Giovanni Vizzini, Bruno Gridelli, Ester Badami, Pier Giulio Conaldi
PURPOSE: Hepatitis C virus (HCV) predominantly infects hepatocytes, although it is known that receptors for viral entry are distributed on a wide array of target cells. Chronic HCV infection is indeed characterized by multiple non-liver manifestations, suggesting a more complex HCV tropism extended to extrahepatic tissues and remains to be fully elucidated. In this study, we investigated the gastrointestinal mucosa (GIM) as a potential extrahepatic viral replication site and its contribution to HCV recurrence...
2017: PloS One
https://www.readbyqxmd.com/read/28748882/superiority-of-peginterferon-%C3%AE-2a-and-ribavirin-combination-over-peginterferon-%C3%AE-2a-monotherapy-in-the-management-of-hemodialysis-patients-with-chronic-hepatitis-c-virus-infection
#13
Saeed M G Al-Ghamdi, Nasser Alaulaqi, Abdullah A Al-Amoudi, Amenah Alghamdi, Abbas Zagnoon, Bakr Ben Sadiq
Hepatitis C virus (HCV) is a common infection affecting 15% of hemodialysis population in Saudi Arabia resulting in delay in transplantation and long-term complications. The use of peginterferon resulted in sustained virologic response (SVR) in 40%-85% of patients, especially if combined with ribavirin. The treatment is hampered by the high dropout due to anemia and requirement of blood transfusion resulting from this therapy. Some studies have shown that the addition of increasing dose of erythropoiesis-stimulating agents (ESA) and reduced dose of ribavirin results in reduced dropout rate with high SVR...
July 2017: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/28748878/assessment-of-hepatic-fibrosis-by-fibroscan-in-egyptian-chronic-hemodialysis-patients-with-chronic-hepatitis-c-genotype-4-a-single-center-study
#14
Bahaa El-Din Moustafa Zayed, Aisha Elsharkawy, Mahmoud Abdou, Dina Sabry Abd Al Fatah, Tarek Hussein El-Shabony
Assessing hepatic fibrosis in hemodialysis patients with chronic hepatitis C (CHC) can help to evaluate the long-term prognosis, complications of hepatitis C virus (HCV) as well as eligibility for renal transplantation,. Our aim was to assess liver fibrosis in Egyptian hemodialysis (HD) patients infected with CHC genotype 4 using a fibroscan. This cross-sectional observational study was conducted over two years on a cohort of 134 Egyptian patients on prevalent HD at Kasr Al Ainy Hospital. All patients were subjected to routine laboratory evaluation including, hepatitis B surface antigen, hepatitis B core antibody, hepatitis Be antigen, hepatitis C antibody (HCVAb) and human immunodeficiency virus antibody, quantitative polymerase chain reaction (PCR) for both HCV and hepatitis B virus (HBV), serum hyaluronic acid level, and alpha-fetoprotein (AFP)...
July 2017: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/28746204/direct-acting-antiviral-agent-efficacy-and-safety-in-renal-transplant-recipients-with-chronic-hepatitis-c-virus-infection-a-prisma-compliant-study
#15
REVIEW
Keliang Chen, Pei Lu, Rijin Song, Jiexiu Zhang, Rongzhen Tao, Zijie Wang, Wei Zhang, Min Gu
BACKGROUND: The efficacy and safety of direct-acting antivirals (DAAs) for treating hepatitis C virus (HCV)-infected renal transplant recipients (RTRs) has not been determined. METHODS: We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials and assessed the quality of eligible studies using the Joanna Briggs Institute scale. DAA efficacy and safety were assessed using standard mean difference (SMD) with 95% confidence intervals (95%CIs)...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28744104/efficacy-and-safety-of-direct-acting-antiviral-therapy-in-previous-hard-to-treat-patients-with-recurrent-hepatitis-c-virus-infection-after-liver-transplantation-a-real-world-cohort
#16
Sebastian Bernuth, Daniel Grimm, Johanna Vollmar, Felix Darstein, Jens Mittler, Michael Heise, Maria Hoppe-Lotichius, Peter R Galle, Hauke Lang, Tim Zimmermann
BACKGROUND: Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) has been a frequent and relevant problem in the past two decades. This analysis evaluated the efficacy and safety of new interferon (IFN)-free direct-acting antiviral (DAA) therapies in a large real-world cohort of HCV patients after LT. METHODS: We retrospectively analyzed a cohort of 157 patients infected with HCV who underwent deceased donor LT between 1997 and 2014. Patient survival, outcome, and side effects of antiviral therapy were assessed...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28736976/living-donor-liver-transplantation-for-neonatal-fulminant-hepatitis-due-to-herpes-simplex-virus-infection
#17
Rodrigo Vincenzi, Eduardo A Fonseca, Karina M O Roda, Gilda Porta, Helry L Candido, Marcel R Benavides, Katia R M Leite, Rogerio C Afonso, Plinio Turine-Neto, Cristiane M F Ribeiro, Paulo Chapchap, João Seda-Neto
Although rare, ALF caused by disseminated HSV infection is associated with high mortality in the neonatal population. This condition is often diagnosed relatively late due to the absence of specific signs. We present a case involving a neonate with ALF submitted to living donor liver transplantation without a prior diagnosis. The patient had no skin or mucosal lesions, and IgM serology was negative for HSV-1 and HSV-2. Immunohistochemical staining of the liver explant was positive for herpes virus infection, and the patient subsequently received antiviral drug treatment, with a good outcome...
July 23, 2017: Pediatric Transplantation
https://www.readbyqxmd.com/read/28736015/fibrosing-cholestatic-hepatitis-c-after-liver-transplantation-therapeutic-options-before-and-after-introduction-of-direct-acting-antivirals-our-experience-and-literature-review
#18
O Tronina, K Ślubowska, N Mikołajczyk-Korniak, E Komuda-Leszek, R Wieczorek-Godlewska, B Łągiewska, M Pacholczyk, W Lisik, M Kosieradzki, M Durlik
BACKGROUND: Cirrhosis caused by hepatitis C is the most common indication for liver transplantation. The most aggressive form of hepatitis C virus (HCV) relapse after liver transplantation is fibrosing cholestatic hepatitis C, which can be observed in 2% to 15% of recipients. METHODS: Double therapy with peg-interferon and ribavirin was characterized by low antiviral response, rapid fibrosis, and frequent graft failure within 1 year after surgery. RESULTS: Introduction of direct-acting antivirals for HCV treatment allows for more efficient therapy with less adverse reactions, including patients with fibrosing cholestatic hepatitis C...
July 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28736010/predictors-of-mortality-in-living-donor-liver-transplantation
#19
S Elkholy, S Mogawer, A Hosny, M El-Shazli, U M Al-Jarhi, S Abdel-Hamed, A Salah, N El-Garem, A Sholkamy, M El-Amir, M S Abdel-Aziz, A Mukhtar, A El-Sharawy, A Nabil
BACKGROUND: Egypt has the highest prevalence of the world hepatitis C virus (HCV) load. Hence, the problem of end-stage liver disease (ESLD) is considered a huge burden on the community. Living donor liver transplantation (LDLT) is the only source of donation in Egypt till now. Survival rates had shown significant improvement in the past decades. This study provides analysis of the mortality rates and possible predictors of mortality following LDLT. It also aids in developing a practical and easy-to-apply risk index for prediction of early mortality...
July 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28732019/rate-of-hepatitis-c-viral-clearance-by-human-livers-in-human-patients-liver-transplantation-modeling-primary-infection-and-implications-for-studying-entry-inhibition
#20
Michael G Hughes, William W Tucker, Sreelatha Reddy, Michael E Brier, David Koch, Craig J McClain, Colleen B Jonsson, Nobuyuki Matoba, Donghoon Chung
To better understand the dynamics of early hepatitis C virus (HCV) infection, we determined how rapidly non-cirrhotic HCV-uninfected liver allografts clear HCV from the circulation of cirrhotic HCV-infected patients at the time of transplantation but before administration of immunosuppression. Specifically, we characterized serum HCV kinetics during the first 90 min of reperfusion for 19 chronically HCV-infected patients transplanted with an HCV-uninfected liver by measuring serum viral load immediately prior to reperfusion (t = 0) and then every 15 min for a total of 90 min (t = 90)...
2017: PloS One
keyword
keyword
112674
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"